



(12) Translation of
European patent specification

(11) NO/EP 3743053 B1

NORWAY

(19) NO
(51) Int Cl.

A61K 31/05 (2006.01)
A61K 31/36 (2006.01)

A61K 31/551 (2006.01)
A61K 45/06 (2006.01)

A61P 25/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.12.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.29
(86)	European Application Nr.	19702670.1
(86)	European Filing Date	2019.01.22
(87)	The European Application's Publication Date	2020.12.02
(30)	Priority	2018.01.24, GB, 201801158
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	GW Research Limited, Sovereign House Vision Park Chivers Way Histon, Cambridge, Cambridgeshire CB24 9BZ, Storbritannia
(72)	Inventor	GUY, Geoffrey, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon Cambridge, Cambridgeshire CB24 9BZ, Storbritannia KNAPPERTZ, Volker, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon Cambridge, Cambridgeshire CB24 9BZ, Storbritannia WHALLEY, Benjamin, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon Cambridge, Cambridgeshire CB24 9BZ, Storbritannia
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54) Title **USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY**

(56) References
Cited:

WO-A1-2016/059403
US-A1- 2017 181 982
GB-A- 2 539 472
EVAN J. HESS ET AL: "Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex", EPILEPSIA, vol. 57, no. 10, 1 October 2016 (2016-10-01), pages 1617-1624, XP55501922, NEW YORK, US ISSN: 0013-9580, DOI: 10.1111/epi.13499
ORRIN DEVINSKY ET AL: "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, vol. 376, no. 21, 25 May 2017 (2017-05-25), pages 2011-2020, XP55581640, US ISSN: 0028-4793, DOI: 10.1056/NEJMoa1611618
EMILIO PERUCCA: "Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?", JOURNAL OF EPILEPSY RESEARCH, vol. 7, no. 2, 28 December 2017 (2017-12-28), pages 61-76, XP55581907, ISSN: 2233-6249, DOI: 10.14581/jer.17012
GEOFFREY A L ET AL: "Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy", EPILEPSIA 20150801 BLACKWELL PUBLISHING INC. USA, vol. 56, no. 8, 1 August 2015 (2015-08-01), pages 1246-1251, XP002790755, ISSN: 0013-9580
S. WRIGHT ET AL.: "CANNABIDIOL (CBD) IN DRAVET SYNDROME: A RANDOMISED, DOSE-RANGING PHARMACOKINETICS AND SAFETY TRIAL (GWPCARE1)", EPILEPSIA, vol. 58(Suppl.5), September 2017 (2017-09), page s56, XP002790754,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Cannabidiol (CBD) for anvendelse i reduksjon av anfall i behandlingsresistent Dravets syndrom, hvori CBD administreres i kombinasjon med stiripentol.
- 5 2. Cannabidiol (CBD) for anvendelse ifølge krav 1, hvori CBD er i form av et godt rensset ekstrakt av cannabis som omfatter minst 98 % (vekt/vekt) CBD.
3. Cannabidiol (CBD) for anvendelse ifølge krav 2, hvori det godt rensede ekstraktet omfatter mindre enn 0,15 % tetrahydrocannabinol (THC).
- 10 4. Cannabidiol (CBD) for anvendelse ifølge krav 2, hvori ekstraktet videre omfatter opptil 1 % cannabidivarin (CBDV).
- 15 5. Cannabidiol (CBD) for anvendelse ifølge krav 1, hvori CBD er til stede som en syntetisk forbindelse.
6. Cannabidiol (CBD) for anvendelse ifølge et hvilket som helst av de foregående kravene, hvori dosen av CBD er under 50 mg/kg/dag.
- 20 7. Cannabidiol (CBD) for anvendelse ifølge et hvilket som helst av de foregående kravene, hvori dosen av CBD er større enn 10 mg/kg/dag.
8. Cannabidiol (CBD) for anvendelse ifølge et hvilket som helst av de foregående kravene, hvori dosen av CBD er større enn 20 mg/kg/dag.